Skip to main content
All lobbying clients

THE CAMPAIGN FOR SUSTAINABLE RX PRICING

Lobbying client · District of Columbia · filed 2025 to 2026

A coalition of organizations working on market-based solutions to drug pricing.

$540,000 Reported spend
6 Filings counted
1 Firms hired
30 Bills named

Spend is reported income plus in-house expenses across 6 filings. Everything on this page is grouped by the client's LDA id (175642), not by name.

 Firms hired 1
 Bills named in these filings 30
  • HR 1843
    To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
    6 filings
  • S 1040
    Drug Competition Enhancement Act
    6 filings
  • S 1041
    Affordable Prescriptions for Patients Act
    6 filings
  • S 1095
    Stop STALLING Act
    6 filings
  • S 1096
    Preserve Access to Affordable Generics and Biosimilars Act
    6 filings
  • S 1097
    Interagency Patent Coordination and Improvement Act of 2025
    6 filings
  • S 229
    DTC Act of 2025
    6 filings
  • S 43
    Skinny Labels, Big Savings Act
    6 filings
  • HR 3269
    ETHIC Act
    5 filings
  • HR 3789
    DTC Act of 2025
    5 filings
  • S 1954
    Biosimilar Red Tape Elimination Act
    5 filings
  • S 2276
    ETHIC Act
    5 filings
  • HR 3010
    No Handouts for Drug Advertisements Act
    4 filings
  • HR 3152
    Patent Eligibility Restoration Act of 2025
    4 filings
  • HR 3160
    PREVAIL Act
    4 filings
  • S 1032
    Major Richard Star Act
    4 filings
  • S 1533
    A bill to amend title 38, United States Code, to make permanent and codify the pilot program for use of contr…
    4 filings
  • S 1546
    Patent Eligibility Restoration Act of 2025
    4 filings
  • S 1785
    No Handouts for Drug Advertisements Act
    4 filings
  • S 2630
    Saving NSF’s Workforce Act
    4 filings
  • HR 1262
    Mikaela Naylon Give Kids a Chance Act
    3 filings
  • S 1067
    Ensuring Timely Access to Generics Act of 2023
    2 filings
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
    2 filings
  • HR 4570
    Interagency Patent Coordination and Improvement Act of 2025
    2 filings
  • HR 5526
    Biosimilar Red Tape Elimination Act
    2 filings
  • HR 6485
    Skinny Labels, Big Savings Act
    2 filings
  • S 1302
    Increasing Transparency in Generic Drug Applications Act
    2 filings
  • S 1414
    Expedited Access to Biosimilars Act
    2 filings
  • S 2658
    Medication Affordability and Patent Integrity Act
    2 filings
  • S 3014
    Ensuring Timely Access to Generics Act of 2025
    2 filings
 Reported by year 2 years
  • 2026 $180,000 2 filings
  • 2025 $360,000 4 filings
 Issues lobbied 4

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 5
  • HOUSE OF REPRESENTATIVES 6
  • SENATE 6
  • Centers For Medicare and Medicaid Services (CMS) 5
  • Health & Human Services, Dept of (HHS) 5
  • Food & Drug Administration (FDA) 2

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem